579 related articles for article (PubMed ID: 29248691)
1. Kratom use and mental health: A systematic review.
Swogger MT; Walsh Z
Drug Alcohol Depend; 2018 Feb; 183():134-140. PubMed ID: 29248691
[TBL] [Abstract][Full Text] [Related]
2. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia.
Singh D; Narayanan S; Vicknasingam B; Corazza O; Santacroce R; Roman-Urrestarazu A
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28544011
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic and clinical assessment of kratom.
White CM
Am J Health Syst Pharm; 2018 Mar; 75(5):261-267. PubMed ID: 29255059
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia.
Singh D; Müller CP; Murugaiyah V; Hamid SBS; Vicknasingam BK; Avery B; Chear NJY; Mansor SM
J Ethnopharmacol; 2018 Mar; 214():197-206. PubMed ID: 29248450
[TBL] [Abstract][Full Text] [Related]
5. Evaluating health information provided to kratom consumers by good manufacturing practice-qualified vendors.
Hill K; Gibson S; Grundmann O; Smith KE; Ballard J; Stanciu CN
Subst Abuse Treat Prev Policy; 2023 Apr; 18(1):21. PubMed ID: 37041624
[TBL] [Abstract][Full Text] [Related]
6. Social Functioning of Kratom (Mitragyna speciosa) Users in Malaysia.
Singh D; Müller CP; Vicknasingam BK; Mansor SM
J Psychoactive Drugs; 2015; 47(2):125-31. PubMed ID: 25950592
[TBL] [Abstract][Full Text] [Related]
7. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research.
Henningfield JE; Fant RV; Wang DW
Psychopharmacology (Berl); 2018 Feb; 235(2):573-589. PubMed ID: 29273821
[TBL] [Abstract][Full Text] [Related]
8. Kratom policy: The challenge of balancing therapeutic potential with public safety.
Prozialeck WC; Avery BA; Boyer EW; Grundmann O; Henningfield JE; Kruegel AC; McMahon LR; McCurdy CR; Swogger MT; Veltri CA; Singh D
Int J Drug Policy; 2019 Aug; 70():70-77. PubMed ID: 31103778
[TBL] [Abstract][Full Text] [Related]
9. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users.
Singh D; Yeou Chear NJ; Narayanan S; Leon F; Sharma A; McCurdy CR; Avery BA; Balasingam V
J Ethnopharmacol; 2020 Mar; 249():112462. PubMed ID: 31816368
[TBL] [Abstract][Full Text] [Related]
10. Experiences of Kratom Users: A Qualitative Analysis.
Swogger MT; Hart E; Erowid F; Erowid E; Trabold N; Yee K; Parkhurst KA; Priddy BM; Walsh Z
J Psychoactive Drugs; 2015; 47(5):360-7. PubMed ID: 26595229
[TBL] [Abstract][Full Text] [Related]
11. Exploring the self-reported motivations of kratom (
Grundmann O; Veltri CA; Morcos D; Knightes D; Smith KE; Singh D; Corazza O; Cinosi E; Martinotti G; Walsh Z; Swogger MT
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):433-444. PubMed ID: 35389321
[No Abstract] [Full Text] [Related]
12. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users.
Singh D; Müller CP; Vicknasingam BK
Drug Alcohol Depend; 2014 Jun; 139():132-7. PubMed ID: 24698080
[TBL] [Abstract][Full Text] [Related]
13. A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans.
Prevete E; Kuypers KPC; Theunissen EL; Corazza O; Bersani G; Ramaekers JG
Hum Psychopharmacol; 2022 Jan; 37(1):e2805. PubMed ID: 34309900
[TBL] [Abstract][Full Text] [Related]
14. Update on the Pharmacology and Legal Status of Kratom.
Prozialeck WC
J Am Osteopath Assoc; 2016 Dec; 116(12):802-809. PubMed ID: 27893147
[TBL] [Abstract][Full Text] [Related]
15. Kratom (Mitragyna speciosa): worldwide issues.
Ramanathan S; McCurdy CR
Curr Opin Psychiatry; 2020 Jul; 33(4):312-318. PubMed ID: 32452943
[TBL] [Abstract][Full Text] [Related]
16. Kratom (Mitragyna speciosa): Friend or Foe?
Sethi R; Hoang N; Ravishankar DA; McCracken M; Manzardo AM
Prim Care Companion CNS Disord; 2020 Jan; 22(1):. PubMed ID: 31999896
[TBL] [Abstract][Full Text] [Related]
17. A Case Report of Kratom Addiction and Withdrawal.
Galbis-Reig D
WMJ; 2016 Feb; 115(1):49-52; quiz 53. PubMed ID: 27057581
[TBL] [Abstract][Full Text] [Related]
18. Clinical Pharmacology of the Dietary Supplement Kratom (Mitragyna speciosa).
Hartley C; Bulloch M; Penzak SR
J Clin Pharmacol; 2022 May; 62(5):577-593. PubMed ID: 34775626
[TBL] [Abstract][Full Text] [Related]
19. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction.
Hassan Z; Muzaimi M; Navaratnam V; Yusoff NH; Suhaimi FW; Vadivelu R; Vicknasingam BK; Amato D; von Hörsten S; Ismail NI; Jayabalan N; Hazim AI; Mansor SM; Müller CP
Neurosci Biobehav Rev; 2013 Feb; 37(2):138-51. PubMed ID: 23206666
[TBL] [Abstract][Full Text] [Related]
20. Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.
Lydecker AG; Sharma A; McCurdy CR; Avery BA; Babu KM; Boyer EW
J Med Toxicol; 2016 Dec; 12(4):341-349. PubMed ID: 27752985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
